IDP.L Regulatory News (IDP)

InnovaDerma PLC

("InnovaDerma" or the "Company")

Allotment of Shares

Further to the announcements made on 2 and 8 May 2017, InnovaDerma (LSE: IDP), a UK developer of life sciences, beauty and personal care products today announces that it has allotted the final consideration of shares to the sellers of Ergon Medical Limited (the "Allottees").

45,249 Ordinary Shares (the "Final Consideration Shares") were allotted as the final consideration of shares to the Allottees following the finalisation of the completion accounts and were allotted at a price of £1.6575 per share. These Final Consideration Shares are in addition to the Ordinary Shares previously issued.

6,930 of the Final Consideration Shares have been issued to the Allottees in certificated form and 38,319 of the Final Consideration Shares have been admitted to CREST. The new Ordinary Shares will rank equally in all respects with the Company's existing Ordinary Shares and will be admitted to trading.

Following the issue of the Final Consideration Shares, the total number of Ordinary Shares in issue is 12,614,804. This number may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.

Further enquiries

About InnovaDerma

InnovaDerma PLC (LSE: IDP) is an emerging leader specializing in the research, manufacture and marketing of clinically proven products in life sciences, beauty, and personal care products. InnovaDerma has presence in the UK, US, Australia, New Zealand, Philippines, South Africa, Hong Kong, and South Korea.

www.innovaderma.com